View : 454 Download: 0
Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
- Title
- Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
- Authors
- Eun, Mi-Yeon; Kim, Jae-Young; Hwang, Yang-Ha; Park, Man-Seok; Kim, Joon-Tae; Choi, Kang-Ho; Jung, Jin-Man; Yu, Sungwook; Kim, Chi Kyung; Oh, Kyungmi; Song, Tae-Jin; Kim, Yong-Jae; Kim, Bum Joon; Heo, Sung Hyuk; Park, Kwang-Yeol; Kim, Jeong-Min; Park, Jong-Ho; Choi, Jay Chol; Chung, Jong-Won; Bang, Oh Young; Kim, Gyeong-Moon; Seo, Woo-Keun
- Ewha Authors
- 송태진
- SCOPUS Author ID
- 송태진
- Issue Date
- 2021
- Journal Title
- JOURNAL OF STROKE
- ISSN
- 2287-6391
2287-6405
- Citation
- JOURNAL OF STROKE vol. 23, no. 1, pp. 113 - +
- Keywords
- Stroke; Atrial fibrillation; Guideline; Anticoagulants; Outcome
- Publisher
- KOREAN STROKE SOC
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background and Purpose To evaluate the outcome events and bleeding complications of the European Society of Cardiology (ESC) guideline-matched oral anticoagulant therapy for patients with acute ischemic stroke and atrial fibrillation (AF). Methods Patients with acute ischemic stroke and AF from a nationwide multicenter registry (Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts [K-ATTENTION]) between January 2013 and December 2015 were included in the study. Patients were divided into the ESC guideline-matched and the non-matched groups. The primary outcome was recurrence of any stroke during the 90-day follow-up period. Secondary outcomes were major adverse cerebrovascular and cardiovascular events, ischemic stroke, intracranial hemorrhage, acute coronary syndrome, all-cause mortality, and major hemorrhage. Propensity score matching and logistic regression analyses were performed to assess the effect of the treatments administered. Results Among 2,321 eligible patients, 1,126 patients were 1:1 matched to the ESC guideline-matched and the non-matched groups. As compared with the non-matched group, the ESC guideline-matched group had a lower risk of any recurrent stroke (1.4% vs. 3.4%; odds ratio [OR], 0.41; 95% confidence interval [CI], 0.18 to 0.95). The risk of recurrent ischemic stroke was lower in the ESC guideline-matched group than in the non-matched group (0.9% vs. 2.7%; OR, 0.32; 95% CI, 0.11 to 0.88). There was no significant difference in the other secondary outcomes between the two groups. Conclusions ESC guideline-matched oral anticoagulant therapy was associated with reduced risks of any stroke and ischemic stroke as compared with the non-matched therapy.
- DOI
- 10.5853/jos.2020.03440
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML